Our laboratory personnel have experience with human and non-human tumor models to evaluate experimental drugs. Our strategy for evaluating new compounds in vivo is to work closely with the sponsor to develop a protocol to evaluate the anti-tumor activity of an agent under optimal conditions.
Adult and Pediatric Tumor Xenograft Models
Combination Studies with Conventional Chemotherapeutics
Multiple Dosing Schedules and Delivery Protocols
Experienced with Small Molecules, Biologicals, Antibody and Antisense Technologies
Steffan Nawrocki, Ph.D.
Co-Director, Preclinical Research
CTRC Institute for Drug Development